Kent Kresa has been chairman of MannKind Corp. since 2016 and has served on the company’s board of directors since 2004. MannKind is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Kresa, a former chairman and chief executive of Northrop Grumman Corp., also serves as chairman emeritus of the company. He helped transform Northrop Grumman from a boutique military contractor to a broad-based $28 billion enterprise with 120,000 employees. Kresa is chairman of the advisory board of Lincoln Laboratory at Massachusetts Institute of Technology, a member of the board of overseers at Keck School of Medicine of USC, chairman emeritus of the Caltech board of trustees and director emeritus of the Los Angeles Music Center
For reprint and licensing requests for this article, CLICK HERE.